On 27 May 2005, orphan designation (EU/3/05/283) was granted by the European Commission to Amgen Europe BV, The Netherlands, for recombinant megakariopoiesis stimulating protein for the treatment of idiopathic thrombocytopenic purpura.
Recombinant megakariopoiesis stimulating protein has been authorised in the EU as Nplate since 4 February 2009.
Recombinant megakaryopoiesis-stimulating protein
|Disease / condition||
Treatment of idiopathic thrombocytopenic purpura
|Date of decision||
|Orphan decision number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.